- Home
- UPST vs RNA Comparison
UPST vs RNA Comparison
Compare UPST & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- RNA
- Stock Information
- Founded
- UPST 2012
- RNA 2012
- Country
- UPST United States
- RNA United States
- Employees
- UPST N/A
- RNA N/A
- Industry
- UPST Finance: Consumer Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- UPST Finance
- RNA Health Care
- Exchange
- UPST Nasdaq
- RNA Nasdaq
- Market Cap
- UPST 3.8B
- RNA 4.0B
- IPO Year
- UPST 2020
- RNA 2020
- Fundamental
- Price
- UPST $38.45
- RNA $70.78
- Analyst Decision
- UPST Buy
- RNA Buy
- Analyst Count
- UPST 15
- RNA 20
- Target Price
- UPST $63.18
- RNA $69.26
- AVG Volume (30 Days)
- UPST 7.6M
- RNA 10.2M
- Earning Date
- UPST 11-04-2025
- RNA 11-10-2025
- Dividend Yield
- UPST N/A
- RNA N/A
- EPS Growth
- UPST N/A
- RNA N/A
- EPS
- UPST 0.26
- RNA N/A
- Revenue
- UPST $997,748,000.00
- RNA $20,868,000.00
- Revenue This Year
- UPST $59.09
- RNA N/A
- Revenue Next Year
- UPST $27.21
- RNA $108.97
- P/E Ratio
- UPST $150.94
- RNA N/A
- Revenue Growth
- UPST 64.93
- RNA 106.27
- 52 Week Low
- UPST $31.40
- RNA $21.51
- 52 Week High
- UPST $96.43
- RNA $71.09
- Technical
- Relative Strength Index (RSI)
- UPST 33.09
- RNA 80.52
- Support Level
- UPST $36.67
- RNA $69.67
- Resistance Level
- UPST $39.96
- RNA $70.98
- Average True Range (ATR)
- UPST 2.35
- RNA 0.28
- MACD
- UPST -0.39
- RNA -0.21
- Stochastic Oscillator
- UPST 15.66
- RNA 84.28
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.